Supplementary Table S2. Active compounds against esophageal cancer.

Number	Name	Target	Cell Viability (100%)
1	Defactinib (VS-6063)	FAK inhibitor	62.19
166	Triapine	DNA/RNA Synthesis inhibitor	61.49
808	Epetraborole hydrochloride	Antibacterial inhibitor	61.49
188	LY-2874455	FGFR inhibitor; VEGFR inhibitor	59.76
455	CH5183284 (Debio-1347)	FGFR inhibitor	59.07
845	Acelarin	DNA/RNA Synthesis inhibitor	58.55
370	STF-31	transporter inhibitor	58.47
325	Ascomycin (FK520)	phosphatase inhibitor	57.66
276	Afuresertib	Akt inhibitor	56.27
286	NLG919	IDO inhibitor	55.62
783	AS-8351	Others inhibitor	55.46
299	CHS 828	NAMPT inhibitor	54.51
561	CDDO (Bardoxolone)	Nrf2 inhibitor	53.02
240	Selumetinib (AZD6244)	MEK inhibitor	50.41
239	2-Amino-6-mercaptopurin	DNA Methyltransferase inhibitor	50.31

	e		
271	Picropodophyllin (PPP)	Adenosine Receptor antagonist; Aurora Kinase inhibitor	48.98
254	Obatoclax Mesylate (GX15-070)	Bcr-Abl antagonist	41.69
159	YM155	Survivin inhibitor	29.28
6	Epirubicin hydrochloride	Topoisomerase inhibitor	15.27
726	Halofuginone hydrobromide	Others inhibitor	7.37
460	Verdinexor (KPT-335)	XPO1 inhibitor	2.30

Supplementary Table S3. Primers used for qPCR analyses.

Gene name	Sequences	
	Forward Primer	Reverse Primer
FOSL1	CAGGCGGAGACTGACAAACTG	TCCTTCCGGGATTTTGCAGAT
GAPDH	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCATACTTCTCATGG

Supplementary Table S4. The sequences of siRNAs used in knockdown experiments.

Gene name	Sequences	
	sense（5'-3'）	antisense（5'-3'）
FOSL1-homo-1210	CUAGCACAAUUUGCACUAATT	UUAGUGCAAAUUGUGCUAGTT
FOSL1-homo-301	GCCAAGCAUCAACACCAUGTT	CAUGGUGUUGAUGCUUGGCTT
FOSL1-homo-926	GCUCAUCGCAAGAGUAGCATT	UGCUACUCUUGCGAUGAGCTT
c-Myc-homo-1344	GAGGAUAUCUGGAAGAAAUTT	AUUUCUUCCAGAUAUCCUCTT
c-Myc-homo-1729	GCUUGUACCUGCAGGAUCUTT	AGAUCCUGCAGGUACAAGCTT
c-Myc-homo-1982	GGAAGAAAUCGAUGUUGUUTT	AACAACAUCGAUUUCUUCCTT
Negative control	UUCUCCGAACGUGUCACGUTT	ACGUGACACGUUCGGAGAATT